Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - methylprednisolone 1000 mg - 1000 mg

Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - fluticasone propionate 0.05 % - 0.05%

Israël - anglais - Ministry of Health

novartis israel ltd - moxifloxacin as hydrochloride - ophthalmic solution - moxifloxacin as hydrochloride 0.5 % - moxifloxacin - moxifloxacin - for the treatment of bacterial conjunctivitis caused by susceptible strains or organisms.

Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية ابن رشد - ibn rushd drug store - loxoprofen sodium anhydrous 60 mg - 60 mg

Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية ابن رشد - ibn rushd drug store - loxoprofen sodium 60 mg - 60 mg

Israël - anglais - Ministry of Health

teva israel ltd - bimatoprost; timolol as maleate - eye drops, solution - timolol as maleate 5 mg / 1 ml; bimatoprost 0.3 mg / 1 ml - timolol, combinations - reduction of intraocular pressure in patients with open- angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues

Israël - anglais - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - film coated tablets - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - non-small cell lung cancer (nsclc):tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer:tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Israël - anglais - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - film coated tablets - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - non-small cell lung cancer (nsclc):tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer:tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Israël - anglais - Ministry of Health

abic marketing ltd, israel - risedronic acid as sodium - film coated tablets - risedronic acid as sodium 150 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

Israël - anglais - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib - film coated tablets - erlotinib 100 mg - erlotinib - non-small cell lung cancer (nsclc):tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer:tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.